批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
>>>原始批准或临时批准<<<
| 审批日期 | 提交号 | 审批结论 | 提交分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
| 2012/08/31 |
ORIG-1(原始申请) |
Approval |
Type 1 - New Molecular Entity |
PRIORITY
|
|
|
>>>补充申请<<<
| 审批日期 | 提交号 | 审批结论 | 补充类别或审批类型 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
| 2025/03/21 |
SUPPL-24(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2025/01/22 |
SUPPL-23(补充) |
Approval |
Labeling-Container/Carton Labels,Labeling-Package Insert |
STANDARD
|
|
|
| 2023/11/16 |
SUPPL-22(补充) |
Approval |
Efficacy-New Indication |
PRIORITY
|
|
|
| 2022/09/09 |
SUPPL-19(补充) |
Approval |
Efficacy-Labeling Change With Clinical Data |
STANDARD
|
|
|
| 2022/01/13 |
SUPPL-18(补充) |
Approval |
Labeling-Package Insert,Labeling-Patient Package Insert |
STANDARD
|
|
|
| 2020/10/23 |
SUPPL-16(补充) |
Approval |
Efficacy-Labeling Change With Clinical Data |
PRIORITY
|
|
|
| 2019/12/16 |
SUPPL-15(补充) |
Approval |
Efficacy-New Indication |
PRIORITY
|
|
|
| 2018/07/13 |
SUPPL-14(补充) |
Approval |
Efficacy-New Indication |
PRIORITY
|
|
|
| 2017/07/24 |
SUPPL-11(补充) |
Approval |
Efficacy-Labeling Change With Clinical Data |
STANDARD
|
|
|
| 2016/10/20 |
SUPPL-9(补充) |
Approval |
Efficacy-Labeling Change With Clinical Data |
STANDARD
|
|
|
| 2016/07/14 |
SUPPL-10(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
| 2015/11/06 |
SUPPL-8(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
| 2015/10/01 |
SUPPL-7(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2015/08/05 |
SUPPL-6(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2015/07/21 |
SUPPL-5(补充) |
Approval |
Efficacy-Labeling Change With Clinical Data |
STANDARD
|
|
|
| 2014/09/10 |
SUPPL-3(补充) |
Approval |
Efficacy-New Indication |
PRIORITY
|
|
|
| 2014/05/23 |
SUPPL-2(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
| 2013/03/19 |
SUPPL-1(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
>>>活性成分:ENZALUTAMIDE; 剂型/给药途径:CAPSULE;ORAL; 规格:40MG; 治疗等效代码:AB<<<
| 申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
| 203415 |
001 |
NDA |
XTANDI |
ENZALUTAMIDE |
CAPSULE;ORAL |
40MG |
Prescription |
Yes |
Yes |
AB |
2012/08/31
|
ASTELLAS |
| 209645 |
001 |
ANDA |
ENZALUTAMIDE |
ENZALUTAMIDE |
CAPSULE;ORAL |
40MG |
Discontinued |
No |
No |
AB |
2022/04/22
|
APOTEX |
| 209667 |
001 |
ANDA |
ENZALUTAMIDE |
ENZALUTAMIDE |
CAPSULE;ORAL |
40MG |
Discontinued |
No |
No |
AB |
2024/09/26
|
ZYDUS PHARMS |